Evidence map›Paper›PMID 42855719›Full record

ArticleExperimental hematology & oncology2026

Beyond MYD88-only testing: MYD88/CD79B profiling improves molecular detection and MCD genotyping in VRL and CNS lymphomas.

Mona M Wang, Yuanhan Li, Gee Fung How, Candice E H Ho, Nagavalli DO Somasundaram, Jason Yongsheng Chan, Timothy Kwang Yong Tay, Than Hein, Anita Sook Yee Chan

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Experimental hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mona M WangMedical Immune Oncology Research Group (MIORG), Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland.ORCID http://orcid.org/0000-0002-4019-0289
Yuanhan LiSingapore National Eye Centre and Singapore Eye Research Institute, Singapore, Singapore.
Gee Fung HowDepartment of Haematology, Singapore General Hospital, Singapore, Singapore.
Candice E H HoSingapore National Eye Centre and Singapore Eye Research Institute, Singapore, Singapore.
Nagavalli DO SomasundaramNational Cancer Centre Singapore, Singapore, Singapore.
Jason Yongsheng ChanNational Cancer Centre Singapore, Singapore, Singapore.
Timothy Kwang Yong TayDuke-NUS Medical School, Singapore, Singapore.ORCID http://orcid.org/0000-0001-8592-5018
Than HeinDepartment of Haematology, Singapore General Hospital, Singapore, Singapore.
Anita Sook Yee ChanSingapore National Eye Centre and Singapore Eye Research Institute, Singapore, Singapore. anita.chan.s.y@singhealth.com.sg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diagnosing rare, aggressive immune-privileged (IP)-large B-cell lymphomas (LBCL), such as primary vitreoretinal lymphoma (VRL) and primary central nervous system lymphoma (CNSL), remains challenging due to the fragility of lymphoma cells within the vitreous or cerebrospinal fluid (CSF) and paucicellular yields, which preclude definitive cytological diagnosis. Clinical MYD88

Identifiers

PMID42855719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.